Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

• The change from baseline in RSI and RFS score during LPRD treatment period, [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  

• Regional difference in distribution of symptoms and lesions, and in severity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  
• LRPD treatment period with rabaprazole sodium [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  

This clinical study is a multicenter, open-label, prospective, observational study of outpatients who visit the department of otolaryngology (branch of medicine that deals with diagnosis and treatment of diseases of the ear, nose, and throat) under routine practice. This study will examine RSI (Reflux Symptom Index) and RFS (Reflux Finding Score) by treatment period (before and after rabeprazole treatment) in patients with LaryngoPharyngeal Reflux Disease(LPRD). Among the patients who visit the department of otolaryngology with suspicious laryngopharyngeal reflux, those needing rabeprazole sodium treatment according to the doctor's discretion are eligible for enrollment. This study will explore the correlation between RSI and RFS and will examine major reflux symptoms and types of lesions, to find the most reliable factors in diagnosing LPRD and judging therapeutic effectiveness of treatments. LPRD is a disease with various symptoms and causes lesions by exposing the upper respiratory system to gastric acid and stomach contents. RSI and RFS can be used to diagnose LPRD in a relatively objective manner by scoring items of symptoms and lesions particular to LPRD. Evaluations will be performed four times from baseline to week 12. Observational Study - one tablet of rabeprazole 10 mg or 20 mg once daily for 12 weeks